IDO1 inhibitors may serve as an “immunometabolic” adjuvant to enhance systemic immune responses and turn immunologically “cold” tumors “hot.” Targeting IDO1 represents a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade [88–90] or adoptive transfer of CAR T cells [91–95]. Here, IDO1 is linked to cancer.